{"transactions":[{"id":1082136,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":77260,"kind":"person","name":"Muralidhar Bali","position":1,"cik":"0001784138","reported_name":"Muralidhar Bali","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-24T23:30:27.000Z","date":"2025-07-22","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares vest on the first anniversary of the Grant Date, provided that the Option will in any case be fully vested on the date of Company's 2026 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the 2020 Equity Incentive Plan (the \"Plan\")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan)."}],"balance_after":30000,"derivative":{"exercise_price":0.1162,"expiration_date":"2035-07-21","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001415889-25-020261","document":"form4-07242025_110724.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000141588925020261/form4-07242025_110724.xml","form_type":"4"}},{"id":1502091,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":77260,"kind":"person","name":"Muralidhar Bali","position":1,"cik":"0001784138","reported_name":"Muralidhar Bali","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-05-24T20:26:36.000Z","date":"2024-05-22","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares vest on the first anniversary of the Grant Date, provided that the Option will in any case be fully vested on the date of Company's 2025 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the 2020 Equity Incentive Plan (the \"Plan\")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan)."}],"balance_after":30000,"derivative":{"exercise_price":0.7511,"expiration_date":"2034-05-21","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001415889-24-014491","document":"form4-05242024_080524.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000141588924014491/form4-05242024_080524.xml","form_type":"4"}},{"id":1861744,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":77260,"kind":"person","name":"Muralidhar Bali","position":1,"cik":"0001784138","reported_name":"Muralidhar Bali","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-08T22:14:59.000Z","date":"2023-06-06","kind":"grant","planned":false,"acquired":true,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest on the earlier of June 6, 2024 or the day prior to the date of the Issuer's 2024 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors."}],"balance_after":17500,"derivative":{"exercise_price":9.01,"expiration_date":"2033-06-05","underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0001209191-23-035563","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1637715/000120919123035563/doc4.xml","form_type":"4"}},{"id":1876601,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":77260,"kind":"person","name":"Muralidhar Bali","position":1,"cik":"0001784138","reported_name":"Muralidhar Bali","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-26T21:38:22.000Z","date":"2023-05-25","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares vest on the first anniversary of the Grant Date, provided that the Option will in any case be fully vested on the date of Company's 2024 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the 2020 Equity Incentive Plan (the \"Plan\")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan)."}],"balance_after":30000,"derivative":{"exercise_price":2.26,"expiration_date":"2033-05-24","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-23-032657","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000120919123032657/doc4.xml","form_type":"4"}},{"id":2231048,"issuer":{"id":8068,"kind":"organization","name":"EXICURE, INC."},"owners":[{"id":77260,"kind":"person","name":"Muralidhar Bali","position":1,"cik":"0001784138","reported_name":"Muralidhar Bali","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2022-06-15T20:17:32.000Z","date":"2022-06-13","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest as to 1/12th of the underlying shares monthly from the vesting commencement date of June 13, 2022, provided the Reporting Person remains in continuous service on each vesting date."}],"balance_after":50000,"derivative":{"exercise_price":0.126,"expiration_date":"2032-06-12","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001209191-22-036942","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1698530/000120919122036942/doc4.xml","form_type":"4"}},{"id":2243668,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":77260,"kind":"person","name":"Muralidhar Bali","position":1,"cik":"0001784138","reported_name":"Muralidhar Bali","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-03T21:00:44.000Z","date":"2022-06-01","kind":"grant","acquired":true,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest on the earlier of June 1, 2023 or the day prior to the date of the Issuer's 2023 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors."}],"balance_after":17500,"derivative":{"exercise_price":2.09,"expiration_date":"2032-05-31","underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0001209191-22-034176","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1637715/000120919122034176/doc4.xml","form_type":"4"}},{"id":2253528,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":77260,"kind":"person","name":"Muralidhar Bali","position":1,"cik":"0001784138","reported_name":"Muralidhar Bali","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-27T20:15:07.000Z","date":"2022-05-25","kind":"grant","acquired":true,"shares":22500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares vest on the first anniversary of the Grant Date, provided that the Option will in any case be fully vested on the date of Company's 2023 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the 2020 Equity Incentive Plan (the \"Plan\")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan)."}],"balance_after":22500,"derivative":{"exercise_price":1.32,"expiration_date":"2032-05-24","underlying":"Common Stock","underlying_shares":22500},"source":{"system":"sec-edgar","filing":"0001209191-22-032507","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000120919122032507/doc4.xml","form_type":"4"}},{"id":2263085,"issuer":{"id":8068,"kind":"organization","name":"EXICURE, INC."},"owners":[{"id":77260,"kind":"person","name":"Muralidhar Bali","position":1,"cik":"0001784138","reported_name":"Muralidhar Bali","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-05-19T20:50:35.000Z","date":"2022-05-19","kind":"purchase","acquired":true,"shares":1472126,"price":0.1937,"value":285150.8062,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held by Abingworth Bioventures VII LP (\"Abingworth VII\"). Abingworth Bioventures VII GP LP serves as the general partner of Abingworth VII. Abingworth General Partner VII LLP, (together with Abingworth Bioventures VII GP LP, the \"General Partners\"), serves as the general partner of Abingworth Bioventures VII GP LP. Abingworth VII (acting by its general partner Abingworth Bioventures VII GP LP, acting by its general partner Abingworth General Partner VII LLP) has delegated to Abingworth LLP all investment and dispositive power over the securities held by Abingworth VII. The Reporting Person, a Director of the Issuer, is a member of an investment committee of Abingworth VII which approves investment and voting decisions by majority vote and no individual member has the sole control or voting power over the securities held by Abingworth VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Each of Abingworth VII, Abingworth LLP, the General Partners, the Reporting Person and each member of the investment committee disclaims beneficial ownership of the common stock held by Abingworth VII, except to the extent of their pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":8449126,"source":{"system":"sec-edgar","filing":"0001209191-22-030549","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1698530/000120919122030549/doc4.xml","form_type":"4"}},{"id":2632941,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":77260,"kind":"person","name":"Muralidhar Bali","position":1,"cik":"0001784138","reported_name":"Muralidhar Bali","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-07-15T21:34:52.000Z","date":"2021-07-14","kind":"purchase","acquired":true,"shares":111736,"price":8.5,"value":949756.0,"ownership":{"direct":false,"nature":"By Abingworth Bioventures 8 LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held by Abingworth Bioventures 8 LP (\"Abingworth 8\"). Abingworth Bioventures 8 GP LP serves as the general partner of Abingworth 8. Abingworth General Partner 8 LLP, (together with Abingworth Bioventures 8 GP LP, the \"General Partners\"), serves as the general partner of Abingworth Bioventures 8 GP LP. Abingworth 8 (acting by its general partner Abingworth Bioventures 8 GP LP, acting by its general partner Abingworth General Partner 8 LLP) has delegated to Abingworth LLP all investment and dispositive power over the securities held by Abingworth 8. The Reporting Person, a Director of the Issuer, is a member of an investment committee of Abingworth 8 which approves investment and voting decisions by majority vote and no individual member has the sole control or voting power over the securities held by Abingworth 8."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Each of Abingworth 8, Abingworth LLP, the General Partners, the Reporting Person and each member of the Investment Committee disclaims beneficial ownership of the common stock held by Abingworth 8, except to the extent of their pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":2073957,"source":{"system":"sec-edgar","filing":"0001209191-21-046803","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1637715/000120919121046803/doc4.xml","form_type":"4"}},{"id":2654397,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":77260,"kind":"person","name":"Muralidhar Bali","position":1,"cik":"0001784138","reported_name":"Muralidhar Bali","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-25T13:00:16.000Z","date":"2021-06-23","kind":"purchase","acquired":true,"shares":20710,"price":9.2827,"value":192244.717,"ownership":{"direct":false,"nature":"By Abingworth Bioventures 8 LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.23 to $9.50 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held by Abingworth Bioventures 8 LP (\"Abingworth 8\"). Abingworth Bioventures 8 GP LP serves as the general partner of Abingworth 8. Abingworth General Partner 8 LLP, (together with Abingworth Bioventures 8 GP LP, the \"General Partners\"), serves as the general partner of Abingworth Bioventures 8 GP LP. Abingworth 8 (acting by its general partner Abingworth Bioventures 8 GP LP, acting by its general partner Abingworth General Partner 8 LLP) has delegated to Abingworth LLP all investment and dispositive power over the securities held by Abingworth 8. The Reporting Person, a Director of the Issuer, is a member of an investment committee of Abingworth 8 which approves investment and voting decisions by majority vote and no individual member has the sole control or voting power over the securities held by Abingworth 8."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of Abingworth 8, Abingworth LLP, the General Partners, the Reporting Person and each member of the Investment Committee disclaims beneficial ownership of the common stock held by Abingworth 8, except to the extent of their pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":1962221,"source":{"system":"sec-edgar","filing":"0000905718-21-000834","document":"reneo_fm4jun232021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1637715/000090571821000834/reneo_fm4jun232021.xml","form_type":"4"}},{"id":2656753,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":77260,"kind":"person","name":"Muralidhar Bali","position":1,"cik":"0001784138","reported_name":"Muralidhar Bali","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-23T12:33:27.000Z","date":"2021-06-22","kind":"purchase","acquired":true,"shares":14615,"price":8.723,"value":127486.645,"ownership":{"direct":false,"nature":"By Abingworth Bioventures 8 LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.55 to $9.30 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held by Abingworth Bioventures 8 LP (\"Abingworth 8\"). Abingworth Bioventures 8 GP LP serves as the general partner of Abingworth 8. Abingworth General Partner 8 LLP, (together with Abingworth Bioventures 8 GP LP, the \"General Partners\"), serves as the general partner of Abingworth Bioventures 8 GP LP. Abingworth 8 (acting by its general partner Abingworth Bioventures 8 GP LP, acting by its general partner Abingworth General Partner 8 LLP) has delegated to Abingworth LLP all investment and dispositive power over the securities held by Abingworth 8. The Reporting Person, a Director of the Issuer, is a member of an investment committee of Abingworth 8 which approves investment and voting decisions by majority vote and no individual member has the sole control or voting power over the securities held by Abingworth 8."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of Abingworth 8, Abingworth LLP, the General Partners, the Reporting Person and each member of the Investment Committee disclaims beneficial ownership of the common stock held by Abingworth 8, except to the extent of their pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":1941511,"source":{"system":"sec-edgar","filing":"0000905718-21-000816","document":"reneo_fm4jun212021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1637715/000090571821000816/reneo_fm4jun212021.xml","form_type":"4"}},{"id":2656752,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":77260,"kind":"person","name":"Muralidhar Bali","position":1,"cik":"0001784138","reported_name":"Muralidhar Bali","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-23T12:33:27.000Z","date":"2021-06-21","kind":"purchase","acquired":true,"shares":32659,"price":9.0305,"value":294927.0995,"ownership":{"direct":false,"nature":"By Abingworth Bioventures 8 LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.55 to $9.50 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held by Abingworth Bioventures 8 LP (\"Abingworth 8\"). Abingworth Bioventures 8 GP LP serves as the general partner of Abingworth 8. Abingworth General Partner 8 LLP, (together with Abingworth Bioventures 8 GP LP, the \"General Partners\"), serves as the general partner of Abingworth Bioventures 8 GP LP. Abingworth 8 (acting by its general partner Abingworth Bioventures 8 GP LP, acting by its general partner Abingworth General Partner 8 LLP) has delegated to Abingworth LLP all investment and dispositive power over the securities held by Abingworth 8. The Reporting Person, a Director of the Issuer, is a member of an investment committee of Abingworth 8 which approves investment and voting decisions by majority vote and no individual member has the sole control or voting power over the securities held by Abingworth 8."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of Abingworth 8, Abingworth LLP, the General Partners, the Reporting Person and each member of the Investment Committee disclaims beneficial ownership of the common stock held by Abingworth 8, except to the extent of their pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":1926896,"source":{"system":"sec-edgar","filing":"0000905718-21-000816","document":"reneo_fm4jun212021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1637715/000090571821000816/reneo_fm4jun212021.xml","form_type":"4"}},{"id":2673288,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":77260,"kind":"person","name":"Muralidhar Bali","position":1,"cik":"0001784138","reported_name":"Muralidhar Bali","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-10T13:00:39.000Z","date":"2021-06-08","kind":"purchase","acquired":true,"shares":16605,"price":9.4977,"value":157709.3085,"ownership":{"direct":false,"nature":"By Abingworth Bioventures 8 LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.44 to $9.50 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held by Abingworth Bioventures 8 LP (\"Abingworth 8\"). Abingworth Bioventures 8 GP LP serves as the general partner of Abingworth 8. Abingworth General Partner 8 LLP, (together with Abingworth Bioventures 8 GP LP, the \"General Partners\"), serves as the general partner of Abingworth Bioventures 8 GP LP. Abingworth 8 (acting by its general partner Abingworth Bioventures 8 GP LP, acting by its general partner Abingworth General Partner 8 LLP) has delegated to Abingworth LLP all investment and dispositive power over the securities held by Abingworth 8. The Reporting Person, a Director of the Issuer, is a member of an investment committee of Abingworth 8 which approves investment and voting decisions by majority vote and no individual member has the sole control or voting power over the securities held by Abingworth 8."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of Abingworth 8, Abingworth LLP, the General Partners, the Reporting Person and each member of the Investment Committee disclaims beneficial ownership of the common stock held by Abingworth 8, except to the extent of their pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":1894237,"source":{"system":"sec-edgar","filing":"0000905718-21-000770","document":"reneo_fm4jun82021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1637715/000090571821000770/reneo_fm4jun82021.xml","form_type":"4"}},{"id":2678745,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":77260,"kind":"person","name":"Muralidhar Bali","position":1,"cik":"0001784138","reported_name":"Muralidhar Bali","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-07T12:53:45.000Z","date":"2021-06-04","kind":"purchase","acquired":true,"shares":257,"price":9.4242,"value":2422.0194,"ownership":{"direct":false,"nature":"By Abingworth Bioventures 8 LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.30 to $9.50 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held by Abingworth Bioventures 8 LP (\"Abingworth 8\"). Abingworth Bioventures 8 GP LP serves as the general partner of Abingworth 8. Abingworth General Partner 8 LLP, (together with Abingworth Bioventures 8 GP LP, the \"General Partners\"), serves as the general partner of Abingworth Bioventures 8 GP LP. Abingworth 8 (acting by its general partner Abingworth Bioventures 8 GP LP, acting by its general partner Abingworth General Partner 8 LLP) has delegated to Abingworth LLP all investment and dispositive power over the securities held by Abingworth 8. The Reporting Person, a Director of the Issuer, is a member of an investment committee of Abingworth 8 which approves investment and voting decisions by majority vote and no individual member has the sole control or voting power over the securities held by Abingworth 8."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of Abingworth 8, Abingworth LLP, the General Partners, the Reporting Person and each member of the Investment Committee disclaims beneficial ownership of the common stock held by Abingworth 8, except to the extent of their pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":1877632,"source":{"system":"sec-edgar","filing":"0000905718-21-000760","document":"reneo_fm4jun32021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1637715/000090571821000760/reneo_fm4jun32021.xml","form_type":"4"}},{"id":2678744,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":77260,"kind":"person","name":"Muralidhar Bali","position":1,"cik":"0001784138","reported_name":"Muralidhar Bali","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-07T12:53:45.000Z","date":"2021-06-03","kind":"purchase","acquired":true,"shares":12100,"price":9.2515,"value":111943.15,"ownership":{"direct":false,"nature":"By Abingworth Bioventures 8 LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.08 to $9.50 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held by Abingworth Bioventures 8 LP (\"Abingworth 8\"). Abingworth Bioventures 8 GP LP serves as the general partner of Abingworth 8. Abingworth General Partner 8 LLP, (together with Abingworth Bioventures 8 GP LP, the \"General Partners\"), serves as the general partner of Abingworth Bioventures 8 GP LP. Abingworth 8 (acting by its general partner Abingworth Bioventures 8 GP LP, acting by its general partner Abingworth General Partner 8 LLP) has delegated to Abingworth LLP all investment and dispositive power over the securities held by Abingworth 8. The Reporting Person, a Director of the Issuer, is a member of an investment committee of Abingworth 8 which approves investment and voting decisions by majority vote and no individual member has the sole control or voting power over the securities held by Abingworth 8."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of Abingworth 8, Abingworth LLP, the General Partners, the Reporting Person and each member of the Investment Committee disclaims beneficial ownership of the common stock held by Abingworth 8, except to the extent of their pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":1877375,"source":{"system":"sec-edgar","filing":"0000905718-21-000760","document":"reneo_fm4jun32021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1637715/000090571821000760/reneo_fm4jun32021.xml","form_type":"4"}},{"id":2680386,"issuer":{"id":8068,"kind":"organization","name":"EXICURE, INC."},"owners":[{"id":77260,"kind":"person","name":"Muralidhar Bali","position":1,"cik":"0001784138","reported_name":"Muralidhar Bali","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-04T21:17:51.000Z","date":"2021-06-02","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest as to 1/12th of the underlying shares monthly from the vesting commencement date of June 2, 2021, provided the Reporting Person remains in continuous service on each vesting date."}],"balance_after":50000,"derivative":{"exercise_price":1.71,"expiration_date":"2031-06-01","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001209191-21-038324","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1698530/000120919121038324/doc4.xml","form_type":"4"}},{"id":2685695,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":77260,"kind":"person","name":"Muralidhar Bali","position":1,"cik":"0001784138","reported_name":"Muralidhar Bali","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-02T14:37:31.000Z","date":"2021-05-28","kind":"purchase","acquired":true,"shares":14,"price":9.5,"value":133.0,"ownership":{"direct":false,"nature":"By Abingworth Bioventures 8 LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held by Abingworth Bioventures 8 LP (\"Abingworth 8\"). Abingworth Bioventures 8 GP LP serves as the general partner of Abingworth 8. Abingworth General Partner 8 LLP, (together with Abingworth Bioventures 8 GP LP, the \"General Partners\"), serves as the general partner of Abingworth Bioventures 8 GP LP. Abingworth 8 (acting by its general partner Abingworth Bioventures 8 GP LP, acting by its general partner Abingworth General Partner 8 LLP) has delegated to Abingworth LLP all investment and dispositive power over the securities held by Abingworth 8. The Reporting Person, a Director of the Issuer, is a member of an investment committee of Abingworth 8 which approves investment and voting decisions by majority vote and no individual member has the sole control or voting power over the securities held by Abingworth 8."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Each of Abingworth 8, Abingworth LLP, the General Partners, the Reporting Person and each member of the Investment Committee disclaims beneficial ownership of the common stock held by Abingworth 8, except to the extent of their pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":1865275,"source":{"system":"sec-edgar","filing":"0000905718-21-000744","document":"reneo_fm4may282021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1637715/000090571821000744/reneo_fm4may282021.xml","form_type":"4"}},{"id":2690635,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":77260,"kind":"person","name":"Muralidhar Bali","position":1,"cik":"0001784138","reported_name":"Muralidhar Bali","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-28T20:10:34.000Z","date":"2021-05-27","kind":"purchase","acquired":true,"shares":1120,"price":9.2583,"value":10369.296,"ownership":{"direct":false,"nature":"By Abingworth Bioventures 8 LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.115 to $9.50 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held by Abingworth Bioventures 8 LP (\"Abingworth 8\"). Abingworth Bioventures 8 GP LP serves as the general partner of Abingworth 8. Abingworth General Partner 8 LLP, (together with Abingworth Bioventures 8 GP LP, the \"General Partners\"), serves as the general partner of Abingworth Bioventures 8 GP LP. Abingworth 8 (acting by its general partner Abingworth Bioventures 8 GP LP, acting by its general partner Abingworth General Partner 8 LLP) has delegated to Abingworth LLP all investment and dispositive power over the securities held by Abingworth 8. The Reporting Person, a Director of the Issuer, is a member of an investment committee of Abingworth 8 which approves investment and voting decisions by majority vote and no individual member has the sole control or voting power over the securities held by Abingworth 8."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of Abingworth 8, Abingworth LLP, the General Partners, the Reporting Person and each member of the Investment Committee disclaims beneficial ownership of the common stock held by Abingworth 8, except to the extent of their pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":1865261,"source":{"system":"sec-edgar","filing":"0000905718-21-000738","document":"reneo_fm4may262021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1637715/000090571821000738/reneo_fm4may262021.xml","form_type":"4"}},{"id":2690634,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":77260,"kind":"person","name":"Muralidhar Bali","position":1,"cik":"0001784138","reported_name":"Muralidhar Bali","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-28T20:10:34.000Z","date":"2021-05-26","kind":"purchase","acquired":true,"shares":5915,"price":9.3821,"value":55495.1215,"ownership":{"direct":false,"nature":"By Abingworth Bioventures 8 LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.14 to $9.46 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held by Abingworth Bioventures 8 LP (\"Abingworth 8\"). Abingworth Bioventures 8 GP LP serves as the general partner of Abingworth 8. Abingworth General Partner 8 LLP, (together with Abingworth Bioventures 8 GP LP, the \"General Partners\"), serves as the general partner of Abingworth Bioventures 8 GP LP. Abingworth 8 (acting by its general partner Abingworth Bioventures 8 GP LP, acting by its general partner Abingworth General Partner 8 LLP) has delegated to Abingworth LLP all investment and dispositive power over the securities held by Abingworth 8. The Reporting Person, a Director of the Issuer, is a member of an investment committee of Abingworth 8 which approves investment and voting decisions by majority vote and no individual member has the sole control or voting power over the securities held by Abingworth 8."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of Abingworth 8, Abingworth LLP, the General Partners, the Reporting Person and each member of the Investment Committee disclaims beneficial ownership of the common stock held by Abingworth 8, except to the extent of their pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":1864141,"source":{"system":"sec-edgar","filing":"0000905718-21-000738","document":"reneo_fm4may262021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1637715/000090571821000738/reneo_fm4may262021.xml","form_type":"4"}},{"id":2700950,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":77260,"kind":"person","name":"Muralidhar Bali","position":1,"cik":"0001784138","reported_name":"Muralidhar Bali","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-05-22T01:08:55.000Z","date":"2021-05-20","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares vest on the first anniversary of the Grant Date, provided that the Option will in any case be fully vested on the date of Company's 2022 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the 2020 Equity Incentive Plan (the \"Plan\")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan)."}],"balance_after":10000,"derivative":{"exercise_price":15.24,"expiration_date":"2031-05-19","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-21-035149","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000120919121035149/doc4.xml","form_type":"4"}},{"id":2748256,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":77260,"kind":"person","name":"Muralidhar Bali","position":1,"cik":"0001784138","reported_name":"Muralidhar Bali","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Preferred Stock","published_at":"2021-04-15T20:15:00.000Z","date":"2021-04-13","kind":"exercise","acquired":false,"shares":7420232,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Abingworth Bioventures 8 LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 4.4748 shares of Preferred Stock. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 4.4748 shares of Preferred Stock. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 4.4748 shares of Preferred Stock. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"See Exhibit 99.1"}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1658226},"source":{"system":"sec-edgar","filing":"0001209191-21-026823","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1637715/000120919121026823/doc4.xml","form_type":"4"}},{"id":2748255,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":77260,"kind":"person","name":"Muralidhar Bali","position":1,"cik":"0001784138","reported_name":"Muralidhar Bali","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-15T20:15:00.000Z","date":"2021-04-13","kind":"purchase","acquired":true,"shares":200000,"price":15,"value":3000000.0,"ownership":{"direct":false,"nature":"By Abingworth Bioventures 8 LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The shares were purchased in the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"See Exhibit 99.1"}],"balance_after":1858226,"source":{"system":"sec-edgar","filing":"0001209191-21-026823","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1637715/000120919121026823/doc4.xml","form_type":"4"}},{"id":2748254,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":77260,"kind":"person","name":"Muralidhar Bali","position":1,"cik":"0001784138","reported_name":"Muralidhar Bali","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-15T20:15:00.000Z","date":"2021-04-13","kind":"exercise","acquired":true,"shares":1658226,"ownership":{"direct":false,"nature":"By Abingworth Bioventures 8 LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 4.4748 shares of Preferred Stock. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"See Exhibit 99.1"}],"balance_after":1658226,"source":{"system":"sec-edgar","filing":"0001209191-21-026823","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1637715/000120919121026823/doc4.xml","form_type":"4"}},{"id":2751066,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":77260,"kind":"person","name":"Muralidhar Bali","position":1,"cik":"0001784138","reported_name":"Muralidhar Bali","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-04-12T19:09:29.000Z","date":"2021-04-08","kind":"grant","acquired":true,"shares":14000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest on April 8, 2022."}],"balance_after":14000,"derivative":{"exercise_price":15,"expiration_date":"2031-04-07","underlying":"Common Stock","underlying_shares":14000},"source":{"system":"sec-edgar","filing":"0001209191-21-026336","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1637715/000120919121026336/doc4.xml","form_type":"4"}},{"id":3005325,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":77260,"kind":"person","name":"Muralidhar Bali","position":1,"cik":"0001784138","reported_name":"Muralidhar Bali","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Preferred Stock","published_at":"2020-10-16T16:24:58.000Z","date":"2020-10-14","kind":"exercise","acquired":false,"shares":10416666,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B Preferred Stock automatically converted into 0.152881822351322 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering on October 14, 2020 (on an adjusted basis, after giving effect to the 1-for-6.541 reverse stock split of the common stock effected by the Issuer on October 2, 2020) The shares have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B Preferred Stock automatically converted into 0.152881822351322 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering on October 14, 2020 (on an adjusted basis, after giving effect to the 1-for-6.541 reverse stock split of the common stock effected by the Issuer on October 2, 2020) The shares have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B Preferred Stock automatically converted into 0.152881822351322 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering on October 14, 2020 (on an adjusted basis, after giving effect to the 1-for-6.541 reverse stock split of the common stock effected by the Issuer on October 2, 2020) The shares have no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Each share of Series B Preferred Stock automatically converted into 0.152881822351322 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering on October 14, 2020 (on an adjusted basis, after giving effect to the 1-for-6.541 reverse stock split of the common stock effected by the Issuer on October 2, 2020) The shares have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held by Abingworth Bioventures VII LP (\"Abingworth VII\"). Abingworth Bioventures VII GP LP (\"Abingworth GP\") serves as the general partner of Abingworth VII. Abingworth General Partner VII LLP (\"Abingworth GP VII\"), serves as the general partners of Abingworth GP. Abingworth VII (acting by its general partner Abingworth GP, acting by its general partner Abingworth GP VII) has delegated to Abingworth LLP (\"ALLP\"), all investment and dispositive power over the securities held by Abingworth VII. ALLP holds the reported securities indirectly through Abingworth VII. The Reporting Person is a Partner of ALLP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person, a Director of the Issuer, is a member of an investment committee of Abingworth VII which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the securities held by Abingworth VII.  Each of Abingworth VII, Abingworth GP, Abingworth GP VII, and each member of the investment committee disclaims beneficial ownership of the shares held by Abingworth VII."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1592518},"source":{"system":"sec-edgar","filing":"0001209191-20-055016","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000120919120055016/doc4.xml","form_type":"4"}},{"id":3005324,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":77260,"kind":"person","name":"Muralidhar Bali","position":1,"cik":"0001784138","reported_name":"Muralidhar Bali","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-10-16T16:24:58.000Z","date":"2020-10-14","kind":"purchase","acquired":true,"shares":200000,"price":15,"value":3000000.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"The shares were purchased in the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held by Abingworth Bioventures VII LP (\"Abingworth VII\"). Abingworth Bioventures VII GP LP (\"Abingworth GP\") serves as the general partner of Abingworth VII. Abingworth General Partner VII LLP (\"Abingworth GP VII\"), serves as the general partners of Abingworth GP. Abingworth VII (acting by its general partner Abingworth GP, acting by its general partner Abingworth GP VII) has delegated to Abingworth LLP (\"ALLP\"), all investment and dispositive power over the securities held by Abingworth VII. ALLP holds the reported securities indirectly through Abingworth VII. The Reporting Person is a Partner of ALLP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person, a Director of the Issuer, is a member of an investment committee of Abingworth VII which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the securities held by Abingworth VII.  Each of Abingworth VII, Abingworth GP, Abingworth GP VII, and each member of the investment committee disclaims beneficial ownership of the shares held by Abingworth VII."}],"balance_after":1792518,"source":{"system":"sec-edgar","filing":"0001209191-20-055016","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000120919120055016/doc4.xml","form_type":"4"}},{"id":3005323,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":77260,"kind":"person","name":"Muralidhar Bali","position":1,"cik":"0001784138","reported_name":"Muralidhar Bali","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-10-16T16:24:58.000Z","date":"2020-10-14","kind":"exercise","acquired":true,"shares":1592518,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B Preferred Stock automatically converted into 0.152881822351322 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering on October 14, 2020 (on an adjusted basis, after giving effect to the 1-for-6.541 reverse stock split of the common stock effected by the Issuer on October 2, 2020) The shares have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held by Abingworth Bioventures VII LP (\"Abingworth VII\"). Abingworth Bioventures VII GP LP (\"Abingworth GP\") serves as the general partner of Abingworth VII. Abingworth General Partner VII LLP (\"Abingworth GP VII\"), serves as the general partners of Abingworth GP. Abingworth VII (acting by its general partner Abingworth GP, acting by its general partner Abingworth GP VII) has delegated to Abingworth LLP (\"ALLP\"), all investment and dispositive power over the securities held by Abingworth VII. ALLP holds the reported securities indirectly through Abingworth VII. The Reporting Person is a Partner of ALLP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person, a Director of the Issuer, is a member of an investment committee of Abingworth VII which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the securities held by Abingworth VII.  Each of Abingworth VII, Abingworth GP, Abingworth GP VII, and each member of the investment committee disclaims beneficial ownership of the shares held by Abingworth VII."}],"balance_after":1592518,"source":{"system":"sec-edgar","filing":"0001209191-20-055016","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000120919120055016/doc4.xml","form_type":"4"}},{"id":3115773,"issuer":{"id":8068,"kind":"organization","name":"EXICURE, INC."},"owners":[{"id":77260,"kind":"person","name":"Muralidhar Bali","position":1,"cik":"0001784138","reported_name":"Muralidhar Bali","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-06-09T20:27:08.000Z","date":"2020-06-04","kind":"grant","acquired":true,"shares":21693,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest as to 1/12 of the underlying shares monthly from the vesting commencement date of June 4, 2020, provided the Reporting Person remains in continuous service on each vesting date."}],"balance_after":21693,"derivative":{"exercise_price":2.79,"expiration_date":"2030-06-03","underlying":"Common Stock","underlying_shares":21693},"source":{"system":"sec-edgar","filing":"0001209191-20-035256","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1698530/000120919120035256/doc4.xml","form_type":"4"}},{"id":3332173,"issuer":{"id":8068,"kind":"organization","name":"EXICURE, INC."},"owners":[{"id":77260,"kind":"person","name":"Muralidhar Bali","position":1,"cik":"0001784138","reported_name":"Muralidhar Bali","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock $0.0001 par value","published_at":"2019-12-23T21:05:13.000Z","date":"2019-12-19","kind":"purchase","acquired":true,"shares":727000,"price":2.75,"value":1999250.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held by Abingworth Bioventures VII LP (\"Abingworth VII\"). Abingworth Bioventures VII GP LP (\"Abingworth GP\") serves as the general partner of Abingworth VII. Abingworth General Partner VII LLP, serves as the general partner of Abingworth GP. Abingworth VII (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner VII LLP) has delegated to Abingworth LLP (\"ALLP\"), all investment and dispositive power over the securities held by Abingworth VII. ALLP holds the reported securities indirectly through Abingworth VII. The reporting person is an employee of ALLP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reporting person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the reporting person or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":6977000,"source":{"system":"sec-edgar","filing":"0000905718-19-000989","document":"exicure_fm4dec192019.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1698530/000090571819000989/exicure_fm4dec192019.xml","form_type":"4"}},{"id":3446537,"issuer":{"id":8068,"kind":"organization","name":"EXICURE, INC."},"owners":[{"id":77260,"kind":"person","name":"Muralidhar Bali","position":1,"cik":"0001784138","reported_name":"Muralidhar Bali","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2019-08-05T20:18:50.000Z","date":"2019-08-02","kind":"grant","acquired":true,"shares":43386,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests in 36 substantially equal monthly installments from August 2, 2019, subject to the Reporting Person's continued service with the Issuer and certain change of control provisions."}],"balance_after":43386,"derivative":{"exercise_price":2.95,"expiration_date":"2029-08-01","underlying":"Common Stock","underlying_shares":43386},"source":{"system":"sec-edgar","filing":"0000905718-19-000661","document":"exicure_fm4aug22019.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1698530/000090571819000661/exicure_fm4aug22019.xml","form_type":"4"}}]}